Overview
Acute megakaryoblastic leukemia (AMKL) is a rare subtype of acute myeloid leukemia characterized by the predominant proliferation of megakaryoblasts. It often presents with unique genetic markers and is associated with specific clinical contexts, such as Down syndrome 1.Diagnosis
Morphological Identification: Megakaryoblasts identified using platelet peroxidase (PPO) reaction and reactivity with antiplatelet monoclonal antibodies 2.
Molecular Markers: Expression of the c-sis gene detected in leukemia cells, with elevated levels post-relapse indicating potential prognostic significance 1.
Cytochemical Challenges: PPO detection is crucial but limited by partial deficiency and requires electron microscopy, making it less practical for routine diagnosis 2.
Immunophenotyping: Utilization of monoclonal and polyclonal antibodies against platelet proteins for reliable differentiation from normal megakaryocyte progenitors 2.Management
Chemotherapy: Specific drug classes and doses are not detailed in the provided abstracts, but standard AML protocols are often adapted 1.
Monitoring: Regular assessment of c-sis gene expression levels may guide therapeutic adjustments, particularly post-relapse 1.Special Populations
Down Syndrome: AMKL in patients with Down syndrome may exhibit distinct molecular profiles, such as c-sis gene expression, warranting tailored monitoring 1.Key Recommendations
Utilize platelet peroxidase (PPO) detection in conjunction with immunophenotyping for accurate diagnosis of AMKL 2 (Evidence: Moderate).
Monitor c-sis gene expression levels as a potential biomarker for disease progression and relapse 1 (Evidence: Weak).
Adapt standard AML treatment protocols considering the unique molecular characteristics of AMKL, especially in patients with Down syndrome 1 (Evidence: Expert opinion).References
1 Sunami S, Fuse A, Simizu B, Eguchi M, Hayashi Y, Sugita K et al.. The c-sis gene expression in cells from a patient with acute megakaryoblastic leukemia and Down's syndrome. Blood 1987. link
2 Breton-Gorius J, Vainchenker W. Immunological and cytochemical characterization of megakaryocytic lineage leukemia. Progress in clinical and biological research 1986. link